NEW YORK, April 29, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Exxon Mobil Corporation (NYSE: XOM), Helmerich & Payne Inc. (NYSE: HP), Baker Hughes Incorporated (NYSE: BHI), Vale SA (NYSE: VALE) and Core Laboratories N.V. (NYSE: CLB). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1749-100free.
Exxon Mobil Corporation Analyst Notes
On April 23, 2014, Exxon Mobil Corporation (ExxonMobil) announced that its employees and retirees have raised a record amount of $13.41 million for the 'United Way of Greater Houston' ("United Way"), a non-profit organization, during its 2013 community campaign. The funds raised through this event will be utilized by the United Way to help families gain financial stability, making sure students achieve academic success and giving seniors the support they need to remain independent. In addition, ExxonMobil's employees and retirees have volunteered nearly 40,000 hours to support the United Way and its affiliate agencies in a wide range of programs. Neil Duffin, President of ExxonMobil Development Company, said, "I congratulate our current and retired employees for their efforts to support the greater Houston community through the United Way." The full analyst notes on ExxonMobil are available to download free of charge at:
Helmerich & Payne Inc. Analyst Notes
On April 24, 2014, shares of Helmerich & Payne Inc. - a contract drilling Company (H&P) declined 5.97% to end the trading session at $107.02 after the Company reported Q2 FY 2014 financial results (period ended March 31, 2014), which missed Wall Street estimates. Net income was $174.6 million or $1.59 per diluted share, compared to net income of $151.1 million or $1.39 per diluted share in Q2 FY 2013. EPS from continuing operation in Q2 FY 2014, excluding special items, were $1.45, trailed Zacks consensus estimate of $1.47. The Company reported Q2 FY 2014 operating revenues of $893.4 million, up 6.6% YoY beating the Zacks consensus estimate of $884.0 million. During the quarter, the Company's operating revenues from U.S. Land operations improved 8.2% YoY to $741.8 million. In the U.S. land segment, the Company expects revenue days (activity) to increase by approximately 7%, sequentially during Q3 FY 2014. The full analyst notes on H&P are available to download free of charge at:
Baker Hughes Incorporated Analyst Notes
On April 24, 2014, Baker Hughes Incorporated's (Baker Hughes) Chairman and CEO, Martin S. Craighead, announced that the Company's Board of Directors has declared the regular quarterly cash dividend of $0.15 per share of common stock payable May 16, 2014, to holders of record on May 5, 2014. The recently announced dividend is unchanged from the dividend announced in the previous quarter. In addition, the Company plans to release its Q2 2014 financial results on July 17, 2014, before the opening of the market. Following the result release, the Company will hold a conference call at 8:30 a.m. ET to discuss the results. As per Zacks consensus estimate, the Company is expected to post EPS of $0.89 in Q2 2014. The full analyst notes on Baker Hughes are available to download free of charge at:
Vale SA Analyst Notes
On April 24, 2014, Vale SA's (Vale) stock moved up 1.99% to close the trading session at $13.86, outperforming the S&P 500 Index, which moved up 0.17%. Shares in Vale opened the session at $13.71 and fluctuated in the range of $13.58 - $14.05. On the same day, a news article on Reuters reported that a Brazilian appeals court has given its decision in favor of Vale in a dispute over taxation of foreign units that last year forced the Company to pay $10 billion (Reais 22.3 billion) in a settlement with Brazil's tax authorities. In addition, the Company informed that it will release its Q1 2014 production and financial results on April 30, 2014, before market opening. The full analyst notes on Vale are available to download free of charge at:
Core Laboratories N.V. Analyst Notes
On April 24, 2014, Core Laboratories N.V.'s (Core Lab) stock plunged 9.22% to end the trading session at $193.99 after the Company posted its Q1 2014 financial results. The Company reported Q1 2014 revenue of $262.9 million, up 0.8% YoY but lagging the Zacks consensus estimate of $283.0 million. Q1 2014 net income attributable to Cora Lab came in at $61.1 million or $1.35 per diluted share, compared to net income of $56.5 million or $1.22 per diluted share in Q1 2013. The Company Q1 2014 adjusted EPS were $1.45, which missed Zacks consensus estimate of $1.46. For Q2 2014, the Company expected revenue in the range of $280 million - $286 million and EPS in the range of $1.48 to $1.53 up 14% YoY. Core Lab is a provider of proprietary and patented reservoir description, production enhancement, and reservoir management services used to optimize petroleum reservoir performance. The full analyst notes on Core Lab are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review